Acute Lymphoblastic Leukemia

This year’s ASCO Annual Meeting included essential research updates across the field.

In this edition, CAR-T trial for leukemia paused after patient death; obesity may increase risk for blood cancer; new CAR T-cell therapies ‘waiting’ for patients with leukemia and more.

CHICAGO — Seventy-six percent of adults with relapsed or refractory B-cell acute lymphoblastic leukemia achieved complete response to treatment with obecabtagene autoleucel, interim results of the pivotal phase 2 FELIX trial showed.

CHICAGO — Fewer than half of adolescents and young adults with acute lymphoblastic leukemia received first-line treatment at a specialized cancer center, despite an association of such treatment with longer survival, study results showed.

In this edition, cross-border partnership takes on survival gap for children with leukemia; ‘paradigm shift’ in transfusion-dependent myelodysplastic syndrome; FDA approves Ayvakit for mastocytosis and more.

In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more.

In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more.

Ponatinib conferred deeper and more durable responses than imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia who received either agent in combination with reduced-intensity chemotherapy.

NEW ORLEANS — Cumulative anesthesia exposure appeared associated with impairments in neurocognitive function among children with high-risk acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among patients with relapsed or refractory B-cell acute lymphoblastic leukemia.